Edition:
United Kingdom

Biomerieux SA (BIOX.PA)

BIOX.PA on Paris Stock Exchange

64.90EUR
4:35pm GMT
Change (% chg)

€-0.50 (-0.76%)
Prev Close
€65.40
Open
€65.40
Day's High
€66.20
Day's Low
€64.90
Volume
84,601
Avg. Vol
112,571
52-wk High
€82.60
52-wk Low
€59.00

Latest Key Developments (Source: Significant Developments)

BioMerieux Launches Biofire Filmarray Pneumonia Panels With FDA Clearance And CE Marking
Tuesday, 13 Nov 2018 

Nov 13 (Reuters) - BIOMERIEUX SA ::BIOMÉRIEUX LAUNCHES THE BIOFIRE® FILMARRAY® PNEUMONIA PANELS WITH FDA CLEARANCE AND CE MARKING.  Full Article

Biomerieux H1 Gross Profit Up At 634 Million Euros
Wednesday, 5 Sep 2018 

Sept 5 (Reuters) - BIOMERIEUX SA ::H1 SALES EUR 1.17 BILLION VERSUS EUR 1.13 BILLION YEAR AGO.GROSS PROFIT FOR H1 CAME TO EUR 634 MILLION OR 54.3% OF SALES, UP FROM 53.3% IN THE PRIOR-YEAR PERIOD.EBITDA AMOUNTED TO EUR 257 MILLION FOR H1, UP 6% COMPARED WITH EUR 242 MILLION IN FIRST-HALF 2017.CONSOLIDATED NET DEBT CAME TO EUR 261 MILLION AT JUNE 30, 2018, VERSUS EUR 156 MILLION AT DECEMBER 31, 2017.TARGETING 2018 ORGANIC SALES GROWTH FOR THE FULL YEAR OF AROUND 9.5%.AIMING TO DELIVER FULL-YEAR CONTRIBUTIVE OPERATING INCOME BEFORE NON-RECURRING ITEMS OF BETWEEN EUR 340 MILLION AND EUR 350 MILLION AT CURRENT EXCHANGE RATES.  Full Article

Biomerieux H1 Revenue Up At 1.17 Billion Euros
Wednesday, 18 Jul 2018 

July 18 (Reuters) - BIOMERIEUX SA ::H1 SALES EUR 1.17 BLN VERSUS EUR 1.13 BILLION YEAR AGO.  Full Article

Biomerieux Q1 Sales Up 3.4 Percent 587 Million Euros
Thursday, 19 Apr 2018 

April 19 (Reuters) - BIOMERIEUX SA ::Q1 SALES EUR 587 MILLION UP 3.4 PERCENT YOY.NET DEBT AMOUNTED TO EUR 84 MILLION AT MARCH 31, 2018, VERSUS EUR 156 MILLION AT DECEMBER 31, 2017.SALES OF CLINICAL APPLICATIONS ROSE BY 13.5% YEAR-ON-YEAR TO EUR 486 MILLION FOR Q1.  Full Article

Biomerieux Acquires Astute Medical Inc. For About $90 Mln In Cash
Wednesday, 4 Apr 2018 

April 4 (Reuters) - BIOMERIEUX SA ::ANNOUNCED ON WEDNESDAY, ACQUISITION OF ASTUTE MEDICAL INC FOR ABOUT $90 MLN IN CASH.ESTIMATED OPERATING EXPENSES RELATED TO ASTUTE FOR REMAINING 9 MONTHS OF YR COULD DRIVE AN IMPACT OF -60 BPS ON 2018 CONTRIBUTIVE OPERATING INCOME .  Full Article

Biomerieux FY ‍Sales Rise 10.2 Pct To EUR 2,288 Million
Tuesday, 23 Jan 2018 

Jan 23 (Reuters) - BIOMERIEUX SA ::‍SALES MOMENTUM IN 2017 WITH 10.2% GROWTH IN SALES TO EUR 2,288 MILLION IN SALES​.NET DEBT AMOUNTED TO EUR 156 MILLION AT DECEMBER 31, 2017, VERSUS EUR 275 MILLION AT DECEMBER 31, 2016..Q4 2017 SALES FOR BIOMÉRIEUX ROSE 8.9% ON Q4 2016​.EXPECTS CONTRIBUTIVE OPERATING INCOME BEFORE NON-RECURRING ITEMS TO BE IN LINE WITH ITS PREVIOUS TARGET.CHANGE IN FEDERAL INCOME TAX RATE WILL IMPACT FISCAL YEAR 2017 WITH A NON-RECURRING AND NON-CASH BENEFIT OF AROUND EUR 30 MLN.BIOMÉRIEUX ESTIMATES EFFECTIVE TAX RATE IN 2018 AT BETWEEN 24% AND 26%.  Full Article

Biomerieux Q3 sales up at ‍​1.67 billion euros
Wednesday, 18 Oct 2017 

Oct 18 (Reuters) - BIOMERIEUX SA ::Q3 SALES EUR ‍​1.67 BILLION VERSUS EUR 1.51 BILLION YEAR AGO.  Full Article

EXCLUSIVE-Brazil prosecutors seek leniency talks with BRF in food fraud probe

PONTA GROSSA, Brazil, Sept 12 Brazilian federal prosecutors probing whether chicken processor BRF SA and certain laboratories colluded to cheat on food safety tests are seeking cooperation from the firms in return for more lenient penalties, a federal prosecutor told Reuters in an interview.